VEGF and mRNA VEGF expression in CSF from Behçet's disease with neurological involvement

Journal of Neuroimmunology

Volumn 213, Issue 1-2, 2009, Pages 148-153

  Hamzaoui, Kamel ^a   Ayed, Khaled ^b   Hamza, M'Hamed ^c   Hamzaoui, Agnès ^a  

^a UNIVERSITY OF TUNIS   (Tunisia)

^b CHARLES NICOLLE HOSPITAL   (Tunisia)

^c Ibn Zhor ^*  (Tunisia)

Author keywords

Cerebrospinal fluid; Inflammation; Neuro Beh et's Disease; VEGF

Indexed keywords

AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA; VASCULOTROPIN;

ADULT; ARTICLE; BEHCET DISEASE; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; BEHCET SYNDROME; BIOLOGICAL MARKERS; BLOOD-BRAIN BARRIER; CD4-POSITIVE T-LYMPHOCYTES; ENCEPHALITIS; FEMALE; HUMANS; LEUKOCYTE COUNT; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RNA, MESSENGER; TUNISIA; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 68049137625     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.05.005     Document Type: Article

References (41)

1. Akman-Demir G., Tüzün E., Içöz S., Yeşilot N., Yentür S.P., Kürtüncü M., Mutlu M., and Saruhan-Direskeneli G. Interleukin-6 in neuro-Behçet's disease: association with disease subsets and long-term outcome. Cytokine 44 (2008) 373-376
2. Al-Araji A., and Kidd D.P. Neuro-Behçet's disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 8 (2009) 192-204
3. Bang D., Choi B., Kwon H.J., Lee E.S., Lee S., and Sohn S. Rebamipide affects the efficiency of colchicine for the herpes simplex virus-induced inflammation in a Behcet's disease mouse model. Eur. J. Pharmacol. 598 (2008) 112-117
4. Ben Dhifallah I., Houman H., Khanfir M., and Hamzaoui K. Endothelial nitric oxide synthase gene polymorphism is associated with Behçet's disease in Tunisian population. Hum. Immunol. 69 (2008) 661-665
5. Benton R.L., and Whittemore S.R. VEGF165 therapy exacerbates secondary damage following spinal cord injury. Neurochem. Res. 28 (2003) 1693-1703
6. Bisser S., Lejon V., Preux P.M., Bouteille B., Stanghellini A., Jauberteau M.O., Buscher P., and Dumas M. Blood-cerebrospinal fluid barrier and intrathecal immunoglobulins compared to field diagnosis of central nervous system involvement in sleeping sickness. J. Neurol. Sci. 193 (2002) 127-135
7. Borhani Haghighi A., Ittehadi H., Nikseresht A.R., Rahmati J., Ghaffari Poorjahromi S., Pourabbas B., Nazarinia M.A., Habibagahi Z., Fattahi M.J., and Ghaderi A. CSF levels of cytokines in neuro-Behçet's disease. Clin. Neurol. Neurosurg. 111 (2009) 507-510
8. Croll S.D., Ransohoff R.M., and Cai N. VEGF-mediated inflammation precedes angiogenesis in adult brain. Exp. Neurol. 187 (2004) 388-40
9. Hamzaoui K., Ayed K., Slim A., Hamza M., and Touraine J. Natural killer cell activity, interferon-gamma and antibodies to herpes viruses in patients with Behçet's disease. Clin. Exp. Immunol. 79 (1990) 28-34
10. Hamzaoui K., Hamzaoui A., Ghorbel I., Khanfir M., and Houman H. Levels of IL-15 in serum and cerebrospinal fluid of patients with Behçet's disease. Scand. J. Immunol. 64 (2006) 655-660
11. Hamzaoui K., Kamoun M., Houman H., Hentati F., Hamza M., Ayed K., and Hamzaoui A. Discrepancies of NKT cells expression in peripheral blood and in cerebrospinal fluid from Behçet's disease. J. Neuroimmunol. 175 (2006) 160-168
12. Hamzaoui K., Houman H., and Hamzaoui A. Regulatory T cells in cerebrospinal fluid from Behçet's disease with neurological manifestations. J. Neuroimmunol. 187 (2007) 201-204
13. Hamzaoui K., Houman H., Hentati F., and Hamzaoui A. BAFF is up-regulated in central nervous system of neuro-Behçet's disease. J. Neuroimmunol. 2008 (2008) 111-114
14. Hentati F., Fredj M., Gharbi N., and Hamida M. Clinical and biological aspects of neuro-Behçet's in Tunisia. In: Wechsler B., and Godeau P. (Eds). Behçet's disease (1993), Amsterdam, Elsevier 415-418
15. Hirohata S., Isshi K., Oguchi H., Ohse T., Haraoka H., Takeuchi A., and Hashimoto T. Cerebrospinal fluid interleukin-6 in progressive neuro-Behcet's syndrome. Clin. Immunol. Immunopathol. 82 (1997) 12-17
16. Houman M.H., Neffati H., Braham A., Harzallah O., Khanfir M., Miled M., and Hamzaoui K. Behçet's disease in Tunisia. Demographic, clinical and genetic aspects in 260 patients. Clin. Exp. Rheumatol. 25 (2007) S58-S64
17. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 335 (1990) 78-80
18. Ishida S., Usui T., Yamashiro K., Kaji Y., Amano S., Ogura Y., Hida T., Oguchi Y., Ambati J., Joan W., Miller J.W., Gragoudas E.S., Yin-Shan N.G., D'Amore P.A., David T., Shima D.T., and Adamis A.P. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J. Exp. Med. 198 (2003) 483-489
19. Jin K.L., Mao X.O., Nagayama T., Goldsmith P.C., and Greenberg D.A. Induction of vascular endothelial growth factor and hypoxia-inducible factor-1 alpha by global ischemia in rat brain. Neuroscience 99 (2000) 577-585
20. Kirk S.L., and Karlik S.J. VEGF and vascular changes in chronic neuroinflammation. J. Autoimmun. 21 (2003) 3-363
21. Manoonkitiwongsa P.S., Schultz R.L., Whitter E.F., and Lyden P.D. Contraindications of VEGF-based therapeutic angiogenesis: effects on macrophage density and histology of normal and ischemic brains. Vascul. Pharmacol. 44 (2006) 316-325
22. Nezu M., Suzuki N., Mizuno H., Takai Y., Misu T., Aoki M., Nakashima I., and Itoyama Y. A case of Neuro-Behçet disease resembling bacterial meningitis. Rinsho Shinkeigaku 48 (2008) 750-753
23. Patel D.V., Neuman M.J., and Hier D.B. Reversibility of CT and MR findings in neuro-Behcet disease. J. Comput. Assist. Tomogr. 13 (1989) 669-673
24. Pay S., Abbasov T., Erdem H., Musabak U., Simsek I., Pekel A., Akdogan A., Sengul A., and Dinc A. Serum MMP-2 and MMP-9 in patients with Behçet's disease: do their higher levels correlate to vasculo-Behçet's disease associated with aneurysm formation?. Clin. Exp. Rheumatol. 25 (2007) S70-S75
25. Poser C.M. Pathogenesis of multiple sclerosis. A critical reappraisal. Acta Neuropathol. 71 (1986) 1-10
26. Proescholdt M.A., Jacobson S., Tresser N., Oldfield E.H., and Merrill M.J. Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J. Neuropathol. Exp. Neurol. 61 (2002) 914-925
27. Quagliarello V., and Scheld W.M. Bacterial meningitis: pathogenesis, pathophysiology, and progress. N. Engl. J. Med. 327 (1992) 864-872
28. Roscoe W.A., Welsh M.E., Carter D.E., and Karlik S.J. VEGF and angiogenesis in acute and chronic MOG (35-55) peptide induced EAE. J. Neuroimmunol. 209 1-2 (2009) 6-15
29. Ruhrberg C. Growing and shaping the vascular tree: multiple roles for VEGF. Bioessays 25 (2003) 1052-1060
30. Ruhrberg C., Gerhardt H., Golding M., et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev. 16 (2002) 2684-2698
31. Saruhan-Direskeneli G., Yentür S.P., Akman-Demir G., Işik N., and Serdaroǧlu P. Cytokines and chemokines in neuro-Behçet's disease compared to multiple sclerosis and other neurological diseases. J. Neuroimmunol. 145 (2003) 127-134
32. Sohn S., Bang D., Lee E.S., Kwon H.J., Lee S.I., and Lee S. Experimental studies on the antiviral agent famciclovir in Behçet's disease symptoms in ICR mice. Br. J. Dermatol. 145 (2001) 799-804
33. Stalmans I., Ng Y.S., Rohan R., et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J. Clin. Invest. 109 (2002) 327-336
34. Stockhammer G., Poewe W., Burgstaller S., Deisenhammer F., Muigg A., Kiechl S., Schmutzhard E., Maier H., Felber S., Schumacher P., Gunsilius E., and Gastl G. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 54 (2000) 1670-1676
35. Tham E., Gielen A.W., Khademi M., Martin C., and Piehl F. Decreased expression of VEGF-A in rat experimental autoimmune encephalomyelitis and in cerebrospinal fluid mononuclear cells from patients with multiple sclerosis. Scand. J. Immunol. 64 (2006) 609-622
36. Tojo M., Zheng X., Yanagihori H., Oyama N., Takahashi K., Nakamura K., and Kaneko F. Detection of herpes virus genomes in skin lesions from patients with Behçet's disease and other related inflammatory diseases. Acta Derm.-Venereol. 83 (2003) 124-127
37. Usui T., Ishida S., and Yamashiro K. VEGF164 (165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest. Ophthalmol. Vis. Sci. 45 (2004) 368-374
38. van Bruggen N., Thibodeaux H., Palmer J.T., Lee W.P., Fu L., Cairns B., Tumas D., Gerlai R., Williams S.P., van Lookeren Campagne M., and Ferrara N. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J. Clin. Invest. 104 (1999) 1613-1620
39. van der Flier M., Stockhammer G., Vonk G.J., Nikkels P.G., van Diemen-Steenvoorde R.A., van der Vlist G.J., Rupert S.W., Schmutzhard E., Gunsilius E., Gastl G., Hoepelman A.I., Kimpen J.L., and Geelen S.P. Vascular endothelial growth factor in bacterial meningitis: detection in cerebrospinal fluid and localization in postmortem brain. J. Infect. Dis. 183 (2001) 149-153
40. Yazici H., and Esen F. Mortality in Behçet's syndrome. Clin. Exp. Rheumatol. 26 (2008) S138-S140
41. Yesilot N., Shehu M., Oktem-Tanor O., Serdaroglu P., and Akman-Demir G. Silent neurological involvement in Behçet's disease. Clin. Exp. Rheumatol. 24 (2006) S65-S70